Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824043 | 0.85 | MAOB (0.52) | ST14MAOAMAOBLTA4HS1PR5 | |
| SCHEMBL30302090 | 0.85 | MAOA (0.44) | CARM1PRMT6ST14ALDH1A1MAPT | |
| SCHEMBL20566300 | 0.85 | MAOA (0.44) | CARM1PRMT6ST14ALDH1A1MAPT | |
| SCHEMBL15127714 | 0.84 | ST14 (0.36) | CARM1PRMT6ST14ALDH1A1MAPT | |
| SCHEMBL9428779 | 0.83 | LPAR1 (0.44) | ST14ALDH1A1MAPTMAOBPGR | |
| SCHEMBL5885219 | 0.82 | ST14 (0.48) | ST14ALDH1A1MAPTLTA4HTRPA1 | |
| SCHEMBL1564074 | 0.80 | LTA4H (0.59) | CARM1PRMT6ST14ALDH1A1MAPT | |
| SCHEMBL921403 | 0.80 | ST14 (0.73) | CARM1PRMT6ST14ALDH1A1MAPT | |
| SCHEMBL16316407 | 0.80 | CARM1 (0.49) | CARM1PRMT6ST14ALDH1A1MAPT | |
| SCHEMBL22440847 | 0.79 | MCL1 (0.43) | ST14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617711-A1 | Amino alcohol derivatives, salts thereof and immunosuppressive agents | Kyorin Pharmaceutical Co., Ltd. (JP) | 2013-07-24 | — | — | EP | disclosed |
| EP-2172472-B1 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | KYORIN SEIYAKU KK (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-1602660-B1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | KYORIN SEIYAKU KK (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7763752-B2 | Amino alcohol derivatives, salts thereof and immunosuppresive agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763752-B2 | Amino alcohol derivatives, salts thereof and immunosuppresive agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763752-B2 | Amino alcohol derivatives, salts thereof and immunosuppresive agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7759326-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7759326-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-7759326-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2172472-A2 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KOHNO YASUSHI | 2008-11-06 | — | — | US | disclosed |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KOHNO YASUSHI | 2008-11-06 | — | — | US | disclosed |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KOHNO YASUSHI | 2008-11-06 | — | — | US | disclosed |
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20060135622-A1 | Amino alcohol derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1602660-A1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6963012-B2 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | disclosed |
| EP-1548003-A1 | AMINO ALCOHOL DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1431275-A1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | CARM1 3135/4885PRMT6 1682/4885ST14 2115/4885 |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | CARM1 3135/4885PRMT6 1682/4885ST14 2115/4885 |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | IL2, TSLP, HLA-DRB1 | CARM1 2762/4885PRMT6 2889/4885ST14 2873/4885 |
| US-20060135622-A1 | Amino alcohol derivative, addition salt thereof, and immunosuppressant | AADAT, BCAT2, ADH1A | CARM1 739/4885PRMT6 358/4885ST14 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.